Perspective Therapeutics, Inc. CATX
AMEX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 6.58% | 76.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.58% | 76.74% | |||
| Cost of Revenue | 0.80% | -35.09% | |||
| Gross Profit | -0.78% | 35.23% | |||
| SG&A Expenses | 11.60% | 0.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.46% | -28.89% | |||
| Operating Income | -3.45% | 29.00% | |||
| Income Before Tax | -3.03% | 31.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.03% | 30.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.28% | 30.14% | |||
| EBIT | -3.45% | 29.00% | |||
| EBITDA | -3.54% | 30.06% | |||
| EPS Basic | 12.18% | 49.87% | |||
| Normalized Basic EPS | 11.52% | 50.92% | |||
| EPS Diluted | 12.18% | 49.87% | |||
| Normalized Diluted EPS | 11.52% | 50.92% | |||
| Average Basic Shares Outstanding | 16.45% | 39.36% | |||
| Average Diluted Shares Outstanding | 16.45% | 39.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||